1.59
6.71%
+0.10
Pre-market:
1.50
-0.09
-5.66%
Sensei Biotherapeutics Inc stock is currently priced at $1.59, with a 24-hour trading volume of 307.11K.
It has seen a +6.71% increased in the last 24 hours and a +60.91% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.51 pivot point. If it approaches the $1.66 resistance level, significant changes may occur.
Previous Close:
$1.49
Open:
$1.46
24h Volume:
307.11K
Market Cap:
$39.88M
Revenue:
-
Net Income/Loss:
$-34.10M
P/E Ratio:
-1.0743
EPS:
-1.48
Net Cash Flow:
$-32.20M
1W Performance:
+1.27%
1M Performance:
+60.91%
6M Performance:
+174.14%
1Y Performance:
+10.03%
Sensei Biotherapeutics Inc Stock (SNSE) Company Profile
Name
Sensei Biotherapeutics Inc
Sector
Industry
Phone
240 243 8000
Address
451 D Street, Suite 710, Boston
Sensei Biotherapeutics Inc Stock (SNSE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-01-21 | Downgrade | Berenberg | Buy → Hold |
Jun-29-21 | Downgrade | Oppenheimer | Outperform → Perform |
Mar-01-21 | Initiated | Berenberg | Buy |
Mar-01-21 | Initiated | Citigroup | Buy |
Mar-01-21 | Initiated | Oppenheimer | Outperform |
Mar-01-21 | Initiated | Piper Sandler | Overweight |
View All
Sensei Biotherapeutics Inc Stock (SNSE) Latest News
Sensei Biotherapeutics (NASDAQ:SNSE) Coverage Initiated at Stephens - Defense World
Defense World
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance
Yahoo Finance
Sensei Biotherapeutics Inc: Rising -26.74% from 52-Week Low, Can the Stock Stay Afloat? – Invest Chronicle - The InvestChronicle
The InvestChronicle
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
GlobeNewswire Inc.
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ... - GlobeNewswire
GlobeNewswire
Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
GlobeNewswire Inc.
Sensei Biotherapeutics Inc Stock (SNSE) Financials Data
Sensei Biotherapeutics Inc (SNSE) Net Income 2024
SNSE net income (TTM) was -$34.10 million for the quarter ending December 31, 2023, a +29.82% increase year-over-year.
Sensei Biotherapeutics Inc (SNSE) Cash Flow 2024
SNSE recorded a free cash flow (TTM) of -$32.20 million for the quarter ending December 31, 2023, a +18.16% increase year-over-year.
Sensei Biotherapeutics Inc (SNSE) Earnings per Share 2024
SNSE earnings per share (TTM) was -$1.22 for the quarter ending December 31, 2023, a +22.78% growth year-over-year.
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Cap:
|
Volume (24h):